Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing

Reuters

2025/09/29

Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing

**Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the China Securities Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571145381"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571145381\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571145381?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 18:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571145381","market":"us","top_or_hot":-1,"title":"Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-29 18:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the <a href=\"https://laohu8.com/S/601066\">China Securities</a> Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02576","symbol_name":"太美醫療科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDLc58x5c:1","article_id":"2571145381","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571145381","pubTimestamp":1759141053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02576":"太美医疗科技","BK1141":"生命科学工具和服务"},"translate_title":"浙江太美医疗科技股份有限公司宣布向证监会提交H股全流通申请，启动转股及香港上市监管审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02576":0.9},"content_text":"Zhejiang Taimei Medical Technology Co. Ltd. Announces CSRC Filing for Full Circulation of H Shares, Initiating Regulatory Review for Share Conversion and Hong Kong Listing\n    \n\n        **Zhejiang Taimei Medical Technology Co. Ltd. Announces Progress in H Share Full Circulation Regulatory Review** Zhejiang Taimei Medical Technology Co. Ltd. (HKEX: 2576) has announced that it has submitted a filing to the China Securities Regulatory Commission (CSRC) regarding the proposed implementation of the full circulation of its H shares. The company is seeking regulatory approval to convert 363,186,467 domestic shares into H shares, which will then be listed on the Hong Kong Stock Exchange. The conversion and listing are subject to approval and the completion of required procedures by the CSRC, the Hong Kong Stock Exchange, and other relevant authorities. Zhejiang Taimei Medical Technology Co. Ltd. is currently undergoing regulatory review and will provide further updates as appropriate. No grant or funding has been announced in connection with this regulatory process, and the application pertains solely to Zhejiang Taimei Medical Technology Co. Ltd.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhejiang Taimei Medical Technology Co. Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}